RCT in 34 adults with moderate-to-severe atopic dermatitis: a single IV dose of the anti-IL-18 antibody aletekitug 2 mg/kg reduced EASI score more than placebo at week 12 (posterior median change −68.3% vs −32.9%), with no serious adverse events.
RCTn = 34
Ellis et al. Clinical and Molecular Effect of the Anti-IL-18 Antibody Aletekitug in Adults With Atopic Dermatitis